References: Treatment-resistant major depression in adults and young people

Australian Government Department of Health and Aged Care. MDMA and psilocybin hub. Woden, ACT: Therapeutic Goods Administration. Accessed November 2024 https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin-hub
Boudieu L, Mennetrier M, Llorca PM, Samalin L. The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review. Pharmaceutics 2023;15(12). https://www.ncbi.nlm.nih.gov/pubmed/38140113
Committee for Evidence-Based Practice. Use of ketamine in psychiatric practice [Clinical Memorandum]. Melbourne, Victoria: Royal Australian and New Zealand College of Psychiatrists; July 2022. https://www.ranzcp.org/getmedia/75baa529-2b71-419f-993a-2ff64ede50fe/cm-use-of-ketamine-in-psychiatric-practice.pdf
Committee for Evidence-Based Practice and Committee for Research. Therapeutic use of psychedelic substances [Clinical Memorandum]. Melbourne, Victoria: Royal Australian And New Zealand College of Psychiatrists; June 2023. https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/therapeutic-use-of-psychedelic-substances
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018;51(1-02):9-62. https://www.ncbi.nlm.nih.gov/pubmed/28910830
Loo C, Glozier N, Barton D, Baune BT, Mills NT, Fitzgerald P, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. Br J Psychiatry 2023;223(6):533-41. https://www.ncbi.nlm.nih.gov/pubmed/38108319
Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49(12):1087–206. https://www.ncbi.nlm.nih.gov/pubmed/26643054
Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021;55(1):7-117. https://www.ncbi.nlm.nih.gov/pubmed/33353391
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383-99. https://www.ncbi.nlm.nih.gov/pubmed/33726522
Nunez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord 2022;302:385-400. https://www.ncbi.nlm.nih.gov/pubmed/34986373
Psychedelic-Assisted Therapy Steering Group. Therapeutic use of MDMA for PTSD and psilocybin for treatment resistant depression [Clinical Memorandum]. Melbourne, Victoria: Royal Australian and New Zealand College of Psychiatrists; 2023. https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/therapeutic-use-of-mdma-for-ptsd-and-psilocybin-for-treatment-resistant-depression
Sachs GS, Yeung PP, Rekeda L, Khan A, Adams JL, Fava M. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Am J Psychiatry 2023;180(3):241-51. https://www.ncbi.nlm.nih.gov/pubmed/36789515
Seshadri A, Prokop LJ, Singh B. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis. J Affect Disord 2024;356:379-84. https://www.ncbi.nlm.nih.gov/pubmed/38537759
Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry 2020;81(3). https://www.ncbi.nlm.nih.gov/pubmed/32316080.
Zheng W, Cai DB, Xiang YQ, Zheng W, Jiang WL, Sim K, et al. Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. J Affect Disord 2020;265:63-70. https://www.ncbi.nlm.nih.gov/pubmed/31957693